IMMULITE 2000 and 2000 XPi TSI Assay
Graves’ disease (GD) is an autoimmune disorder caused by the presence of thyroid stimulating immunoglobulins (TSI) that bind to the TSH receptor on the thyroid cells and stimulate the uncontrolled production of thyroid hormones. Detecting the presence of TSI in the blood is a powerful diagnostic tool for the differential diagnosis of GD.
TSI measurements are also used to monitor the response to GD therapy and prediction of remission or relapse, confirm Graves’ ophthalmopathy, and predict neonatal thyroid hyperthyroidism.1,2
The IMMULITE® 2000 and 2000 XPi TSI assay is the first automated, quantitative TSI assay available. TSH receptor antibody (TRAb) assays detect both thyroid-blocking and -stimulating antibodies. However, blocking antibodies inhibit TSH stimulation of thyroid cells and lead to hypothyroidism. The IMMULITE 2000 and 2000 XPi TSI assay detects thyroid stimulating antibodies, the specific cause of GD pathology, with a clinical sensitivity and specificity of 98.3% and 99.7% respectively. With a 65-minute total assay time and ready-to-use, stable reagents, the use of this assay can make the differential diagnosis of GD faster and easier, allowing patients to be diagnosed and treated sooner.
¿Fue útil esta información?
Gupta, Manjula K. Thyrotropin-receptor antibodies in thyroid diseases: advances in detection techniques and clinical applications. Clinica Chimica Acta. 2000;293:1-29
Bjorgaas MR, Farstad H, Christiansen SC, Blaas H-GK. Impact of thyrotrophin receptor antibody levels on fetal development in two successive pregnancies in a woman with Graves' disease. Horm Res Paediatr. 2013;79(1):39-43.M.R.